Pfizer, Inc. (PFE) is undergoing a massive transformation over the past two years driven by the new CEO. Once complete it will be a whole new ballgame for Pfizer. The company will be focused on research & development for prescription medicines. It will only be involved with consumer healthcare products and off-patent and generic products through joint ventures. Pfizer may be an interesting pick for investors seeking yield, dividend growth, and potential for capital gains. The current yield is over 4.7%, which is more than double that of the S&P 500. The dividend